Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07617337 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 5 to 7 Eligibility criteria expanded, about 63 words · Secondary endpoints: details revised at 2 of 14 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 63 words
    • Secondary endpoints: details revised at 2 of 14 entries
  2. Recruitment opened Trial sites expanded: 0 → 5 locations · Start date changed from estimate of Jul 31, 2026 to Jul 24, 2026v2 Show 2 more changesShow less
    • Trial sites expanded: 0 → 5 locations
    • Start date changed from estimate of Jul 31, 2026 to Jul 24, 2026
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as single agent and in combination with lorlatinib in patients with ALK positive non-small cell lung cancer.
Trial Details
NCT Number NCT07617337
Lead Sponsor Chugai Pharmaceutical
Conditions ALK Positive Non-small Cell Lung Cancer
Enrollment 102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov